QUOTE AND NEWS
Business Wire  Jan 25  Comment 
Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company developing and commercializing best in class oncology and CNS therapeutics, today announced the publication of preclinical results for RX-5902 in Bioorganic &
Business Wire  Jan 18  Comment 
Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company developing and commercializing oncology and CNS therapeutics, today announced that it has secured Hungarian Regulatory Authority and Ethics Committee approval for
Business Wire  Jan 17  Comment 
Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company commercializing oncology and CNS therapeutics, today provided guidance on its key pipeline, scientific and business goals for 2012. “Rexahn has made the decision
Penny Stock DD  May 16  Comment 
Radient Pharmaceuticals Corporation (AMEX:RPC) reported the fall of 6.25% to close at $0.30 with overall traded volume of 4.45 million shares in the last trading day. The current market price is 28.81% less than its last 50 days simple moving...
Penny Stock DD  Apr 27  Comment 
Rexahn Pharmaceuticals, Inc. (AMEX:RNN) surged by 6.09% to close at $1.22 with overall traded volume of 1.40 million shares in the last trading day. The current market price is 11.43% less than its last 50 days simple moving average. The relative...
Penny Stock DD  Apr 4  Comment 
Rexahn Pharmaceuticals, Inc. (AMEX:RNN) surged by 0.85% to close at $1.19 with overall traded volume of 1.72 million shares in the last trading day. The current market price is 19.85% less than its last 50 days simple moving average. The RSI value...
StreetInsider.com  Mar 31  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Rexahn+%28RNN%29+Closes+%2410M+Direct+Offering/6400485.html for the full story.
StreetInsider.com  Mar 23  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Rexahn+%28RNN%29+Achieves+33%25+Enrollment+for+Serdaxin+Phase+IIb/6383880.html for the full story.
StreetInsider.com  Mar 7  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Management+Changes/Rexahn+Pharma+%28RNN%29+CEO+Transitions+Role/6348582.html for the full story.
StreetInsider.com  Feb 28  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Rexahn%27s+%28RNN%29+Quinoxalinyl-Piperazine+Granted+European+Patent/6327987.html for the full story.





 




References

Wikinvest © 2006, 2007, 2008, 2009, 2010. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki